Effect of propolis on diabetes mellitus

The effect of propolis tablet on glycemic control, lipid profile and insulin resistance in comparison with placebo in patients with type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014080218659N1

Enrollment

Registered

2015-09-07

Start date

2014-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Patients in intervention group receive propolis tabletes,3 times a day, for 12 weeks.Each tablet contains 300 mg propolis. Intervention 2: Patients in control group, receive placebo ta

Treatment - Drugs

Patients in intervention group receive propolis tabletes,3 times a day, for 12 weeks.Each tablet contains 300 mg propolis.

Patients in control group, receive placebo tablets 3 times a day for 12 weeks

Eligibility

Sex/Gender

All

Age

25 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with type 2 diabetes mellitus, diagnosed 5-10 years ago, under treatment with oral hypoglycemic agents. Exclusion criteria: pregnancy, lactation, insulin therapy, any other diseases such as autoimmune, intestinal, liver, thyroid and cardiovascular diseases, vitamin and mineral supplementation, history of dermal or digestive hypersensitivity to propolis, any severe respiratory disease (such as asthma, chronic bronchitis), report of side effects of propolis tablets.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting Blood Glucose. Timepoint: Before and after intervention. Method of measurement: Enzymatic method (mg/dl).;Fasting insulin. Timepoint: Before and after intervention. Method of measurement: ELISA(mU/l).;Triglyceride. Timepoint: Before and after intervention. Method of measurement: Enzymatic method (mg/dl).;Total cholesterol. Timepoint: Before and after intervention. Method of measurement: Enzymatic method (mg/dl).;LDL-C. Timepoint: before and after intervention. Method of measurement: Friedewald formula (mg/dl).;HDL-C. Timepoint: before and after intervention. Method of measurement: Precipitation(mg/dl).;Insulin resistance, sensitivity. Timepoint: Before and after intervention. Method of measurement: Software.	—

Measure

Time frame

Fasting Blood Glucose. Timepoint: Before and after intervention. Method of measurement: Enzymatic method (mg/dl).;Fasting insulin. Timepoint: Before and after intervention. Method of measurement: ELISA(mU/l).;Triglyceride. Timepoint: Before and after intervention. Method of measurement: Enzymatic method (mg/dl).;Total cholesterol. Timepoint: Before and after intervention. Method of measurement: Enzymatic method (mg/dl).;LDL-C. Timepoint: before and after intervention. Method of measurement: Friedewald formula (mg/dl).;HDL-C. Timepoint: before and after intervention. Method of measurement: Precipitation(mg/dl).;Insulin resistance, sensitivity. Timepoint: Before and after intervention. Method of measurement: Software.

—

Secondary

Measure	Time frame
HA1C. Timepoint: The baseline and three months after the intervention. Method of measurement: Turbidometry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNazli Samadi Bilehsavar

Shahid Sadooghi University of Medical Sciences and Health

nazlisamadi510@gmail.com+98 35 3624 0691

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 10, 2026